RVMD · Revolution Medicines, Inc.
$188.75
+3.13% last session
End-of-day data · updated 2026-07-25
Market cap
$40B
Enterprise value
$39B
Trailing P/E
—
Forward P/E
-32.6
Dividend yield
—
Beta
1.38
Avg volume
3M
Employees
1K
2D change
0.25%
5D change
4.90%
10D change
2.60%
30D change
6.21%
60D change
22.17%
MTD change
0.92%
YTD change
137.58%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RVMD
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-23
Latest call per bank · past 12 months
RBC Capital
Outperform$182
-3.6% vs priceWells Fargo
Overweight$167
-11.5% vs priceJP Morgan
Overweight$122
-35.4% vs priceGoldman Sachs
Buy$73.00
-61.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-23 | Wedbush | Maintains | Outperform | $181 → $192 |
| 2026-07-20 | Needham | Maintains | Buy | $235 → $236 |
| 2026-07-09 | Guggenheim | Maintains | Buy | $205 → $235 |
| 2026-07-06 | HC Wainwright & Co. | Reiterates | Buy | $195 |
| 2026-07-06 | Mizuho | Maintains | Outperform | $185 → $215 |
| 2026-07-02 | Wedbush | Maintains | Outperform | $165 → $181 |
| 2026-06-30 | Truist Securities | Maintains | Buy | $179 → $210 |
| 2026-06-29 | Needham | Maintains | Buy | $183 → $235 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 62 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 13.2% above the 50-day MA ($166.82).
- Price vs 200-day MA: Trading 69.6% above the 200-day MA ($111.27).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-1.45) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($192.62).
RVMD Price Chart
Loading chart for RVMD…
Fundamentals
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$121B 5.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$69B -14.8% YTD
ARGX
argenx SE
$57B 9.2% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -31.7% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.7% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.3% YTD
INCY
Incyte Corporation
$24B 19.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.